Your Location:
Home >
Browse articles >
Shexiang Baoxin Pills in Regulation of Angiogenesis in Coronary Heart Disease: A Review
Updated:2022-09-01
    • Shexiang Baoxin Pills in Regulation of Angiogenesis in Coronary Heart Disease: A Review

    • LI Pengqi , XIN Qiqi , YUAN Rong , MIAO Yu , CONG Weihong
    • Chinese Journal of Experimental Traditional Medical Formulae Vol. 28, Issue 14, Pages: 242-253(2022)
    • DOI: 10.13422/j.cnki.syfjx.20220809     

      CLC:

    Scan QR Code

  •  
  •  
  • Full Text(HTML)

  • Figs( 0 ) Tabs( 4 )

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

492

Views

801

Downloads

3

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Effect of Salvianolic Acid B on Angiogenesis of Ischemic Myocardium in Myocardial Ischemia Rats
Dynamic Observation and Mechanism of Qishen Yiqi Drop Pills on Myocardial Ischemia in Rats Based on Angiogenesis
Iron Homeostasis Imbalance Promotes Atherosclerosis and Therapeutic Mechanisms of Traditional Chinese Medicine
Mechanism of Huoxin Pills in Stabilizing Atherosclerotic Vulnerable Plaque Based on Network Pharmacology and Metabolomics
Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory

Related Author

CHEN Heng-xia
XU Li
XU Bo-hua
ZHANG Teng
ZHANG Mi-xia
ZHANG Yan-jun
WANG Maohong
XIONG Jianhua

Related Institution

Jiangxi University of Chinese Medicine
The Affiliated Hospital of Jiangxi University of Chinese Medicine
School of Chinese Materia Medica,Guangzhou University of Chinese Medicine
Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Guangzhou Caizhilin Pharmaceutical Co. Ltd.